How Nerve Recovery Max is said to work, and where the federal record stops

Check 01

What the documents support, as far as they go

A page with this title sets an expectation: that a reader will be told what the capsule does. This one walks as far as the documents go.

No mechanism appears among those steps, and that is not a violation. A supplement is not required to publish one, and an invented mechanism would be worse than none. Two kinds of silence are worth separating: a manufacturer saying nothing about how a product works is lawful and ordinary, while a federal agency having published nothing about an ingredient at all is a different fact, and here it covers six of the ten. This panel carries no proprietary blend. No group of ingredients shares one declared weight, so every amount here is the manufacturer’s own printed figure and none had to be derived from a declaration order.

Check 02

The only federal neuropathy conclusion on this label, and the hedge inside it

NCCIH is the only federal page this desk opened that states a neuropathy conclusion for any ingredient here, and it is hedged in its own sentence.

The sentence is NCCIH’s: “alpha-lipoic acid might be helpful for reducing pain associated with diabetic neuropathy” ^NCCIH. Read the verb. Might be helpful is the agency’s own wording, and the same page prints the count behind it: “3 studies found improvements in symptoms, and 5 studies did not.” ^NCCIH Eight studies, three one way and five the other. That is a doubt stated as a conclusion, which is what an agency sentence looks like when the evidence is split.

The panel prints 400 mg of alpha lipoic acid per serving, 12 g across a bottle, which makes it the heaviest declared thing here. The figure NIH describes is 600 mg a day, in trials of 6 months to 4 years in people with diabetic polyneuropathy ^{NIH ODS}. Both numbers are published rather than one inferred.

Check 03

The one printed amount that lands inside a published range

This check comes out in the product’s favour, and it is written at the same length as the ones that do not.

NIH ODS, in its thiamin fact sheet, reports: “Three studies found that, compared to placebo, 120–900 mg/day benfotiamine with or without other B-vitamins decreased the severity of neuropathy symptoms” ^{NIH ODS}. The panel prints 150 mg of benfotiamine per serving, 4.5 g across a bottle. 150 mg is inside 120 to 900 mg a day. This is the one amount on the panel that sits inside a range a federal source publishes for this condition. NIH calls in the same breath for larger and longer studies.

Three things have to be said together. The range is real and the printed amount is inside it. The sentence reports what three studies found rather than stating an agency conclusion. And the same paragraph asks for better work: “Well-designed studies with larger sample sizes and longer durations are required” ^{NIH ODS}. A page printing the first and leaving out the other two would be selling; one burying the first would be campaigning.

The third row is the one most easily misread. NIH ODS does not mention neuropathy of any kind on its carnitine page. The only doses it publishes are for a different condition entirely. Even there the finding is qualified: “The effects of acetyl-L-carnitine supplements in Alzheimer’s disease and other forms of dementia remain unclear” ^{NIH ODS}.

Check 04

What the agency that owns this condition publishes

Diabetic peripheral neuropathy is NIDDK’s subject. It writes the patient page, it defines the condition, and it is the federal body a reader with numb feet is most likely to be pointed at by a clinician. On supplements it has one sentence.

Read what that is and what it is not. It is not a finding that supplements do not work, not a warning and not a prohibition. It is the absence of a recommendation from the agency best placed to make one, which is weaker than a negative finding and far weaker than an endorsement.

NIDDK owns this condition and publishes the sentence these pages treat as the most important on them: “For safety reasons, talk with your doctor before using supplements or any complementary or alternative medicines.” ^NIDDK Peripheral neuropathy has causes that need diagnosing, and some are treatable. A reader who buys a bottle instead of keeping an appointment has made the one decision this page would most like to prevent.

• This page promises no result. Nothing here says Nerve Recovery Max will reduce pain, restore sensation or repair a nerve.
• It promises no timeline. The timeline page sets out why.
• It is not a diagnosis and not a substitute for one. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Check 05

Three questions behind the phrase, and where each one stops

The heading is three questions wearing one coat. Here the first two are answered in full and the third is not answered at all.

The third tab decides the page. Assembling paragraphs about what ashwagandha is traditionally held to do and presenting them as an account of this capsule would be fiction with citations attached, and for six of the ten there is no federal paragraph to borrow. What would change this page is short: a trial on the finished formula, or a mechanism statement with something behind it.